- Home
- FGEN vs CVKD Comparison
FGEN vs CVKD Comparison
Compare FGEN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- CVKD
- Stock Information
- Founded
- FGEN 1993
- CVKD 2022
- Country
- FGEN United States
- CVKD United States
- Employees
- FGEN N/A
- CVKD N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- FGEN Health Care
- CVKD Health Care
- Exchange
- FGEN Nasdaq
- CVKD Nasdaq
- Market Cap
- FGEN 33.5M
- CVKD 29.5M
- IPO Year
- FGEN 2014
- CVKD 2023
- Fundamental
- Price
- FGEN $8.07
- CVKD $11.92
- Analyst Decision
- FGEN Strong Buy
- CVKD Strong Buy
- Analyst Count
- FGEN 1
- CVKD 1
- Target Price
- FGEN $250.00
- CVKD $32.00
- AVG Volume (30 Days)
- FGEN 60.0K
- CVKD 35.5K
- Earning Date
- FGEN 08-05-2025
- CVKD 08-06-2025
- Dividend Yield
- FGEN N/A
- CVKD N/A
- EPS Growth
- FGEN N/A
- CVKD N/A
- EPS
- FGEN N/A
- CVKD N/A
- Revenue
- FGEN $6,996,000.00
- CVKD N/A
- Revenue This Year
- FGEN N/A
- CVKD N/A
- Revenue Next Year
- FGEN N/A
- CVKD N/A
- P/E Ratio
- FGEN N/A
- CVKD N/A
- Revenue Growth
- FGEN N/A
- CVKD N/A
- 52 Week Low
- FGEN $4.50
- CVKD $5.70
- 52 Week High
- FGEN $38.25
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- FGEN 65.01
- CVKD 36.41
- Support Level
- FGEN $7.03
- CVKD $11.15
- Resistance Level
- FGEN $5.73
- CVKD $13.63
- Average True Range (ATR)
- FGEN 0.58
- CVKD 0.99
- MACD
- FGEN 0.33
- CVKD 0.01
- Stochastic Oscillator
- FGEN 94.43
- CVKD 29.49
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.